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ing the first recommendation in favour of the innovation, and then subsequent
entrants’ prices are reduced through procurement competition as well as their
lower likely required R&D investments. CONCLUSIONS: The study finds that HTA
decisions on medical devices can have a material impact on the market dynamics
(and so prices) following a recommendation, because of themanner inwhichmed-
ical devices are procured. The findings of HTAwill therefore vary depending on the
point in time when it is undertaken, as relative prices change substantially over
time. Re-reviewing cost-effectiveness, without any new clinical evidence, relative
to a technology that has had a ‘disinvestment recommendation’ would therefore
appear perverse, as it sets up a feedback loop that causes a perpetual downward
spiral in prices. The study raises a number of policy issues for consideration. These
include the interplay between different drivers of value in HTA and procurement,
and the implicit ‘genericisation’ of evidence through the procurement process.
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SHOULD PATIENTS BE ALLOWED TO CO-PAY FOR DEVICES AND
TECHNOLOGIES IN THE FUTURE?
Patel D
Double Helix Consulting Group, LONDON, UK
OBJECTIVES: The current global economic climate is putting increasing pressure
on governments and payers to cut health care cost but continue to fund and grant
reimbursement to innovative Medicines, Devices & Biotechnologies that demon-
strate benefit to patient’s quality of life. One fundingmodel that is attracting inter-
est is patient co-payment (co-pay). Patient co-paymodels are being used globally to
allow patient access to medicines and medical technologies. However in United
Kingdom and Europe these types of funding models are still being evaluated and
assessed. A survey was designed to uncover the attitudes of physicians and pa-
tients towards co-pay models as potential funding mechanism for gaining access
to new and innovative technologies.METHODS: The United Kingdomwas selected
to carry out research to gauge the opinions of physicians and patients towards
co-pay. A total of 150 specialist physicians involved in making budget decisions
were surveyed via an internet based questionnaire and in a second survey 558
patients were interviewed face to face to evaluate their attitudes towards co-pay
for new and novel technologies. The results from these two surveys were statisti-
cally analysed to reveal the attitudes of these two key groups toward patient co-pay
and draw some initial conclusions. RESULTS: The analysis and results from the
patient survey showed that 83% of patients would consider co-pay as way of gain-
ing access to new technologies that were not fully reimbursed by the UK public
healthcare system. The physician’s survey showed that 72% of the 150 of specialist
supported the co-pay concept in principle. CONCLUSIONS: This UK research con-
cluded that both physicians and patients would consider co-pay as a funding op-
tion to gain access to new technologies. Additional stakeholder research is antici-
pated to answer the implications surrounding equity and coverage and provide
multiple stakeholders with insights into novel funding mechanisms for new tech-
nologies.
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OBJECTIVES: Concerns have been raised regarding growth in advanced diagnostic
imaging use. This study evaluated national outpatient MRI/CT utilization rates
during 2000-2009 and factors associated with imaging utilization.METHODS: This
retrospective database analysis used data on all respondents in the nationally
representative U.S. Medical Expenditure Panel Survey (MEPS) during 2000-2009.
Visits involving advanced diagnostic imaging were identified based on self-re-
ported use of MRI or CT tests at emergency rooms, office-based medical providers,
and outpatient departments. The imaging utilization rate was defined as the num-
ber of outpatient visits with MRI/CT per 1,000 person-years. Results were weighted
to create nationally representative estimates at the person-year level for each year
and the pooled 10-year period. A multivariate logistic regression was estimated to
identify predictors of imaging use. RESULTS: A total of 319,246 person-years were
included in the analysis. MRI/CT utilization rates increased from 64.3 to 109.1 per
1,000 person years from 2000 to 2009, with older persons, females and Medicare
enrollees having higher rates of use. Growth in imaging slowed in recent years; the
average annual decline in the imaging growth rate was larger than that for all
outpatient services (4.7% vs. 0.9%). The percentage of respondentswithMRI/CT use
(6.7% during 2000-2009) also increased at a slower rate in later years and declined
during 2007-2009. The average number of MRI/CT visits among imaging users was
steady at about 1.5 visits during 2000-2009. Age, female gender, white race, HMO
participation, and all payer types (vs. uninsured) were significant predictors of
imaging use. Compared to 2005, years 2000-2003 were associated with a signifi-
cantly lower likelihood of imaging use , while years 2004-2009 were not signifi-
cantly associated, suggesting a slow-down in later years. CONCLUSIONS: Growth
in advanced imaging utilization appears to have slowed in recent years, a finding of
potential interest to policy-makers and payers.
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Lockwood C1, Marinoni G1, Gallo P2, Kowal S2
1IHS, London, UK, 2IHS, Washington, DC, USA
OBJECTIVES: The objective of this research was to examine how regulatory re-
quirements in the inpatient setting impact the uptake and subsequent market
presence of MDDs (medical devices and diagnostics).METHODS: Primary research
was conducted through 48 in-depth interviews ranging from 30 to 60 minutes in
length. Subjects selected represent key stakeholders from industry, insurance,
government, and health services across 9 major markets (EU 5, United States, Ja-
pan, Canada, and Australia). Interview questionnaires were designed to under-
stand the national opportunities, market access barriers, and cross-country mar-
ket dynamics. This was complemented by secondary desk research that included
literature reviews, government and other relevant agency websites, and IHS pro-
prietary Healthcare and Pharmaceutical services. RESULTS: The study found that
the uptake of innovative devices is affected by the reimbursement environment in
hospitals as these serve as the largest consumers ofMDDs.While hospitals operate
under either global budgets or activity-based funding (DRG system), both funding
mechanismspossess limitations to the uptake of new technologies acrossmarkets.
Under global budgets, MDDs compete against other technologies and procedures
for budget allocation whereas DRG systems use a flat reimbursement rate that acts
as a financial disincentive to use more expensive technologies. Interviewees also
highlighted additional levers that can affect MDD update, including infrequent
coding system revisions, infrequent tariff updates for payments, and the existence
of add-on funding mechanisms, which differ across markets. CONCLUSIONS:
Across the markets considered, the inpatient reimbursement framework tends to
make for fragmented and subpar uptake of innovative MDDs. Indeed, the hospital
funding systems and notably infrequent revision of DRG codes, tariff updates and
complex top-up payment systems, when they exist, hamper new technology up-
take in an industry where incremental innovation is rapid.
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A REVIEW OF HEALTH TECHNOLOGY ASSESSMENTS (HTAS) FOR CERVICAL
CANCER SCREENING TECHNOLOGIES
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OBJECTIVES: To conduct a review of cervical cancer screening HTAs to understand
how new technologies are evaluated. METHODS: The INAHTA website, CRD (Uni-
versity of York) and Avalere CER Intelligence databases, Google, and country
agency websites were searched for “cervical cancer screening” and “HTA” pub-
lished 2000–2011. Reports unrelated to a screening intervention or not fully avail-
able in English were excluded. Topics, technologies, clinical results, primary or
literature-based economic analysis, and incremental cost-effectiveness ratios (IC-
ERs) were abstracted and analyzed. RESULTS: Twenty-five cervical cancer HTA
reports were identified and 17 HTAs from 9 countries met inclusion criteria. Five
technology types were evaluated: 2 cytology tests (conventional cytology (CC), liq-
uid-based cytology (LBC)), 2 Human papillomavirus (HPV) molecular tests, and 1
computer-guided screening system. All 17 HTAs evaluated test sensitivity and
specificity as themeasures of clinical effectiveness. An ICER result was included in
11HTAswith 73% (8/11) of recommendations derived fromprimary economic anal-
ysis. All eight HTAs reporting primary economic analysis incorporated sensitivity
analyses to test various screening intervals. Six reports addressed cost-effective-
ness of LBC compared to CC. Of these, 66% (4/6) concluded that LBC can be a
cost-effective strategy compared to CC at specified intervals. HPV versus cytology
as a primary screening test was an increasingly common topic; comparing 2000-
2005 to 2006-2011, this topic’s inclusion increased 63% (from 43% (3/7) - 70% (7/10)).
One of three HTAs reporting an ICER for HPV primary screening concluded it is
a cost-effective strategy within the context of the screening program.
CONCLUSIONS: Over the last 12 years, seventeen HTAs on cervical cancer screen-
ing evaluated the role of cytology and molecular testing as a primary screening
intervention. Incremental cost-effectiveness (9/17), test sensitivity and specificity
(17/17) and the ability to extend screening intervals (8/17) were the most common
measures used in HTA to evaluate new screening technologies.
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OBJECTIVES: The purpose of this study is to better quantify how urine drug mon-
itoring (UDM) is used in clinical practice. While several published studies have
reported utilization of UDM in clinical practice, little is known about how often
patients are monitored, which patients are monitored, which substances are im-
portant to detect, and under what circumstances clinicians modify the frequency
of monitoring. METHODS: An online survey was developed based on qualitative
phone interviews with eight clinicians who use UDM as a routine component of
clinical practice. One thousand fourteen randomly selected clinicians known to
order urine toxicology screenings were invited by mail to respond to the online
survey assessing their clinical needs and preferences with regards to UDM. Ninety-
three responses were received before the online survey was closed. RESULTS: Of
the 93 respondents, 43% (n40) self-identified as painmanagement specialists and
another 42% (n39) as family/internal medicine practitioners. Seventy-six percent
of respondents (n72) require all new patients to have UDM performed when they
enter their clinic. The majority administer UDM to chronic opioid therapy patients
four times a year. Overall, the respondents showed broad support to test patients
consistently for themost common illicit drugs, themajority of opioids, and a hand-
ful of prescription medications associated with abuse. Ninety-one percent of re-
spondents stated that all of their patients are tested for the same substances,
regardless of abuse history. The most common reasons cited by clinicians for a
change in the frequency of monitoring are patient history of substance abuse and
aberrant behaviors. CONCLUSIONS: Despite a lack of agreement between guide-
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lines informing the use of UDM, there appears to be a general consensus among
practitioners that utilize UDMon:which patients tomonitor, how often tomonitor,
and which substances are most important to detect.
MEDICAL DEVICE/DIAGNOSTICS – Research on Methods
PMD55
PREDICTIVE ACCURACY OF METHODS FOR IDENTIFYING PATIENTS RECEIVING
PERITONEAL DIALYSIS AND HEMODIALYSIS USING HEALTH CARE
ADMINISTRATIVE DATA
Taneja C1, Berger A1, Lamerato L2, Inglese G3, Sloand JA3, Abbott G3, Sheehan MJ2,
Oster G1
1Policy Analysis Inc. (PAI), Brookline, MA, USA, 2Henry Ford Health System, Detroit, MI, USA,
3Baxter Healthcare Corporation, McGaw Park, IL, USA
OBJECTIVES: To estimate the predictive accuracy of methods used to identify pa-
tients receiving peritoneal dialysis (PD) and hemodialysis (HD) in healthcare ad-
ministrative data. METHODS: The study population consisted of all persons aged
18-63 years with evidence of end-stage renal disease (ESRD) who were members of
a large US urban health maintenance organization between January 1, 2005 and
December 31, 2008 (“study period”). Using healthcare administrative data, we iden-
tified all those with any dialysis-related procedure or diagnosis codes; the date of
each patient’s first such encounterwas then designated as the “anchor date”. Using
only codes in healthcare administrative data within 30 days of anchor date, we
then designated each patient as either PD or HD. Medical records were then re-
viewed by trained abstractors using a 180-day window around each patient’s an-
chor date to ascertain positive predictive value (PPV) of procedure and diagnosis
codes in administrative data for receipt of PD and HD. RESULTS: We identified a
total of 233 patients with ESRD and one or more healthcare encounters with dial-
ysis-related procedure and diagnosis codes. Of these, 43 had codes suggesting
receipt of PD, and 173 had codes suggesting receipt of HD; dialysis modality could
not be determined for the remaining 17 patients. PPV of PD-related codes for iden-
tifying patients receiving PD within 30 days of anchor date was 34.9%; it was 67.4%
within both 90 days and 180 days of anchor date. PPV of HD-related codes for
identifying patients receiving HD within 30 days of anchor date was 86.7%; it was
90.8% within 90 days of anchor date, and 93.1% within 180 days of this date.
CONCLUSIONS: While HD-related procedure and diagnosis codes appear to have
relatively high predictive accuracy for identifying patients receiving HD, predictive
accuracy of the codes used to identify patients receiving PD is much lower.
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OBJECTIVES: Observational health care data are often used to study patient popu-
lations and outcomes of interest. Electronic Health Record (EHR) data provide a
granular and longitudinal look at patient care; however, much information is bur-
ied within the narrative text of clinical notes and is not typically available for
research. Diagnosis and procedure codes pose two difficulties when identifying
central venous catheter (CVC) episodes: 1) they are underused and 2) they are
associated with the encounter and not the actual CVC event. METHODS: We ap-
plied advanced healthcare data analyticswith natural language processing (NLP) to
extractmeaningful information about patient care from text clinical information in
the Veteran Affairs nationwide EHR database. The NLP was designed to help iden-
tify and characterize CVC episodes for patients with an inpatient encounter. Pa-
tients were characterized as having (a) a billing code for catheter insertion and (b)
having had a chest x-ray during an inpatient encounter where the presence of a
CVC was identified by NLP. RESULTS: 1.2M patients with an inpatient encounter
were found in the VA between January 1, 2006-December 31, 2010. Of them, 54,676
patients were identified as having at least one inpatient CVC episode using billing
codes. 119,768 additional patients were preliminarily identified via NLP, resulting
in a total of 174,444 CVC patients. CONCLUSIONS: Fifteen percent of inpatients had
a CVC placed and 69% of CVC patients were only identified via NLP. These rates are
consistentwith previously published literature. Thiswork shows thatNLP provides
an effective way to leverage rich observational data. We will use this to study
health outcomes in relation to the catheter placement and related interventions.
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HEALTH OUTCOMES: THE CASE OF RENAL DENERVATION FOR RESISTANT
HYPERTENSION
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OBJECTIVES: Probabilistic sensitivity analysis (PSA) repeatedly runs a simulation
model with randomly selected inputs to characterize the plausible distributions of
projected outcomes. In cost-effectiveness analysis, PSA results are conventionally
displayed as incremental cost-effectiveness scatter plots or cost-effectiveness ac-
ceptability curves. We explored patient-relevant health outcomes other than
QALYs and investigated approaches for displaying probabilistically generated val-
ues, using the case of catheter-based renal denervation (RDN) for resistant
hypertension. METHODS: A Markov model with 54 input distributions simulated
the impact of RDN on stroke, myocardial infarction (MI), coronary heart disease
(CHD), heart failure (HF), end-stage renal disease (ESRD), cardiovascular (CV) and
all-cause death based on the Symplicity HTN-2 RCT and the literature. We report
medians and 95% credible intervals (95% CI), defined as containing 95% of all sim-
ulation results, of 10-year relative risk reductions. One-sample t-tests and ANOVA
were used to compare posterior distributions. Additional analyses evaluated alter-
native time horizons, with values ranging from one year to lifetime. RESULTS:
Relative risk reductions over ten years (95% CI) were: stroke 31.4% (23.1; 36.0%), MI
30.0% (8.9; 38.1%), CHD 22.2% (9.0; 29.4%), HF 13.9% (11.0; 21.7%), ESRD 30.7% (28.8;
34.5%), CV death 30.3% (12.6; 35.7%), and all-cause death 14.4% (4.1; 20.1%). All
clinical outcomes were significantly different from 0% and between each other
(p0.0001). Distribution dotplots, cumulative hazard curves, and survival curves
with 95% credibility intervals were developed as graphic representations of prob-
abilistic results. CONCLUSIONS:Whilemodel-based projections suggest that cath-
eter-based renal denervation leads to clinically and statistically significant event
reductions across clinical outcomes, considerable differences exist between the
distributions of individual reductions. Graphic, probabilistic representation of pa-
tient-relevant endpoints may facilitate a deeper understanding of uncertainty as-
sociated with the long-term clinical effectiveness of new therapies. In addition to
informing clinicians and payers, the proposed conceptual approach could also
contribute to patient education and shared decision making.
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OBJECTIVES: The conventional incremental cost-effectiveness ratio (ICER) and
cost-per-expected life in patients undergoing prolonged mechanical ventilation
(PMV), stratified by different underlying diseases, were determined. METHODS: A
nationwide sample of 50,481 patients who had received continualmechanical ven-
tilation for more than 21 days was collected during 1997-2007. After stratifying the
patients according to specific diagnoses, a latent class analysis (LCA) was per-
formed to categorize PMV patients with multiple co-morbidities into several ho-
mogeneous groups. The survival functions were estimated for individual groups
using the Kaplan-Meier method and extrapolated to 300 months through a semi-
parametricmethod. The survival functions were adjusted with a utility valuemea-
sured by EQ-5D from a convenient sample of 142 PMV patients to estimate the
quality-adjusted life expectancies (QALE). The lifetime expenditures paid by Na-
tional Health Insurance (NHI) were estimated bymultiplying the average spending
with the survival probability for different duration-to-dates and summed up for
different groups. RESULTS: The results showed that PMV therapy costs over
58,000 USD (U.S.dollars) per QALY for almost all patients with poor cognition.
For patients with partial cognition, PMV therapy costs less than 33,000 USD per
QALY for those with cancer, liver cirrhosis, intracranial or spinal cord injuries,
or multiple co-morbidities who are less than 65 years of age; it costs about
52,000-63,400 USD per QALY for those with end stage renal disease, degenera-
tive neurological diseases, or multiple co-morbidities over age 85. All costs-per-
expected life were below 38,000 USD except for those with a longer life expec-
tancy or QALE. CONCLUSIONS: The conventional ICER for PMV varies greatly
depending on the different underlying causes and co-morbidities. The mainte-
nance treatment for PMV patients with poor cognition is the least cost-effective.
The indicator of cost-per-expected life could be considered to improve fairness
in resource allocation.
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OBJECTIVES: Little is known about the acquisition of Clostridium difficile infection
(CDI) and whether it represents hospital- or community-acquired infection. The
objective of this study is to test the feasibility and value of using national hospital
admissions data from Hospital Episode Statistics to examine trends in CDI in
England.METHODS: Hospital Episode Statistics from the period 1997/98 to 2009/10
were used. Time trends were analysed using two different denominators of hospi-
tal activity: total admissions and total bed-days. We explored the impact of so-
ciodemographic factors, comorbidity and healthcare pathways on the risk of CDI.
RESULTS: CDI rates per admission and per bed-days increased from 1997/98 to
2006/07, then decreased significantly by 50% from 2008/9 and 2009/10. This pat-
tern was similar for patients regardless of probable source of infection but the
proportion of probable community-acquired CDI cases rose steadily from 7% in
1997/98 to 13% in 2009/10. CDI rates were higher among older patients (odds ratio:
65 years, 10.9), those with more comorbid conditions (odds ratio for Charlson
index: 5, 5.6), and among patients admitted as an emergency compared with
elective admissions, but no relationship was found with deprivation score.
CONCLUSIONS: Our findings support not only the falling trend in CDI found in the
national mandatory surveillance scheme from the Health Protection Agency, but a
growing proportion of CDI presenting on admission with no evidence of prior hos-
pital exposure in the previous 90 days. We suggest that these may be community-
acquired CDI cases.
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